Bayer enters fray for immune-boosting cancer drugs with Compugen deal
This article was originally published in Scrip
Executive Summary
Bayer is collaborating with Israeli biotech company Compugen to develop drugs that helps the immune system fight cancer.
You may also be interested in...
BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration
Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in combination with its own antibody Opdivo. Combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT, is also on the cards for the future.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.